UNCY

MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.

NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geor.

Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions

A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options. A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options.

New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 30, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly never inspecting the third-party manufacturing facility that had already triggered one Complete Response Letter. NEW YORK, Oct. 29, 2026 /PRNewswire/ -- SueWallSt notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026.

New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026

Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc. Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc.

A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection. NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action naming Chief Executive Officer Shalabh Gupta and Chief Financial Officer John Townsend as individual defendants has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026.